Head-to-head evidence
Anhui HygeianCells EE001 vs iPSC-CL
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
Anhui HygeianCells EE001
Developed by Anhui HygeianCells BioMedical
NCT06884111 · Phase 1 · completed
Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.
iPSC-CL
Developed by HeartWorks
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT05647213 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anhui HygeianCells EE001's landscape · iPSC-CL's landscape